This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;104(15):6779-6789.
doi: 10.1007/s00253-020-10710-z. Epub 2020 Jun 15.

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine

Affiliations

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine

Ran Wang et al. Appl Microbiol Biotechnol. 2020 Aug.

Abstract

Zika virus (ZIKV) and Japanese encephalitis virus (JEV) are closely related to mosquito-borne flaviviruses. Japanese encephalitis (JE) vaccine SA14-14-2 has been in the Chinese national Expanded Program on Immunization since 2007. The recent recognition of severe disease syndromes associated with ZIKV, and the identification of ZIKV from mosquitoes in China, prompts an urgent need to investigate the potential interaction between the two. In this study, we showed that SA14-14-2 is protective against ZIKV infection in mice. JE vaccine SA14-14-2 triggered both Th1 and Th2 cross-reactive immune responses to ZIKV; however, it was cellular immunity that predominantly mediated cross-protection against ZIKV infection. Passive transfer of immune sera did not result in significant cross-protection but did mediate antibody-dependent enhancement in vitro, though this did not have an adverse impact on survival. This study suggests that the SA14-14-2 vaccine can protect against ZIKV through a cross-reactive T cell response. This is vital information in terms of ZIKV prevention or precaution in those ZIKV-affected regions where JEV circulates or SA14-14-2 is in widespread use, and opens a promising avenue to develop a novel bivalent vaccine against both ZIKV and JEV. KEY POINTS: • JEV SA14-14-2 vaccine conferred cross-protection against ZIKV challenge in mice. • T cell immunity rather than antibody mediated the cross-protection. • It provides important information in terms of ZIKV prevention or precaution.

Keywords: Cross-protection; Cross-reactivity; Japanese encephalitis virus; SA14-14-2 vaccine; T cell; Zika virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Cross-reactive protection against ZIKV in SA14-14-2-immunized Ifnar1-/- mice. a Schedule. Female Ifnar1-/- mice were immunized three times at 3-week intervals. Three weeks after the final vaccination, the Ifnar1-/- mice were challenged i.c. with a lethal dose of JEV or ZIKV. Body weight and mortality were monitored daily for 14 consecutive days. b Percentage changes in body weight. Data were expressed as mean ± SD. c Survival rate was shown as the percentage of survivors (n = 6). Mice exhibiting more than 25% loss in weight were humanely euthanized for ethical reasons. Each experiment was independently repeated three times. Asterisk indicates P < 0.05; double asterisk indicates P < 0.01; triple asterisk indicates P < 0.001
Fig. 2
Fig. 2
Cross-reactive nAb responses in mouse sera. a Schedule. Female adult C57BL/6 mice were immunized as previously described. Sera were collected and mixed with either JEV (Beijing-1 strain) or ZIKV (SMGC-1 strain). Then, serum/virus mixture was gently injected i.c. into neonatal C57BL/6 mice. b Serum cross-reactive nAb titers assayed by PRNT50 (n = 7). NAb titers are expressed as GMT + SD. c, d In vitro neutralizing and passive cross-protective effects of immune sera (n = 8, 8, 10, 12, respectively). The mice were monitored daily for body weight and survival rate for 31 consecutive days. c Body weight was expressed as mean ± SD. d Survival rate was shown as the percentage of survivors. Triple asterisk indicates P < 0.001; NS, non-significant
Fig. 3
Fig. 3
Cross-reactive IgG and its subclass responses and ADE in mouse sera. a Schedule of mouse immunization and serum collection. Female adult C57BL/6 mice were immunized three times at 3-week intervals. Sera were collected 3 weeks after the final immunization. b Cross-reactive IgG responses detected by ELISA (n = 7). Ab titers are recorded as GMT + SD. c Cross-reactive IgG subclass responses determined by ELISA (n = 7). d ADE in sera measured by plaque forming (n = 7 per dilution). Asterisk indicates P < 0.05; double asterisk indicates P < 0.01; triple asterisk indicates P < 0.001
Fig. 4
Fig. 4
Cross-reactive cytokine responses in mouse splenocytes. a Schedule. Three weeks after the final immunization, splenocytes from adult C57BL/6 mice were collected. b The cytokines IL-2, IL-4, and IFN-γ secreted by splenocytes were determined using ELISPOT (n = 7). The numbers of cytokine-positive cells are reported as the mean SFU/3 ×ばつ 105 splenocytes + SD. Asterisk indicates P < 0.05; double asterisk indicates P < 0.01; triple asterisk indicates P < 0.001
Fig. 5
Fig. 5
Adoptive transfer of splenocytes from SA14-14-2-vaccinated C57BL/6 mice and cross-protection of splenocytes in Ifnar1-/- mice. a Schedule. Splenic lymphocytes (3 ×ばつ 106 cells per mouse) collected 3 weeks post final immunization were adoptively transferred r.o. to naïve adult mice, and 1 day later mice were challenged with a lethal dose of either JEV or ZIKV. As a control, splenic lymphocytes from PBS-treated mice were transferred to naïve mice prior to challenge. Results were evaluated for b body weight change and c survival rate of mice 14 consecutive days post challenge (n = 6). Mice exhibiting more than 25% loss in weight were humanely euthanized for ethical reasons. Each experiment was independently repeated three times. Results are expressed as mean ± SD. Asterisk indicates P < 0.05; double asterisk P < 0.001

References

    1. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Loriere E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48–53. doi: 10.1038/nature18938. - DOI - PubMed
    1. Breitbach ME, Newman CM, Dudley DM, Stewart LM, Aliota MT, Koenig MR, Shepherd PM, Yamamoto K, Crooks CM, Young G, Semler MR, Weiler AM, Barry GL, Heimsath H, Mohr EL, Eichkoff J, Newton W, Peterson E, Schultz-Darken N, Permar SR, Dean H, Capuano S, 3rd, Osorio JE, Friedrich TC, O'Connor DH. Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques. PLoS Pathog. 2019;15(8):e1007766. doi: 10.1371/journal.ppat.1007766. - DOI - PMC - PubMed
    1. Chang HH, Huber RG, Bond PJ, Grad YH, Camerini D, Maurer-Stroh S, Lipsitch M. Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. Bull World Health Organ. 2017;95(7):517–525I. doi: 10.2471/BLT.16.182105. - DOI - PMC - PubMed
    1. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA, Mongkolsapaya J, Screaton GR. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17(9):1102–1108. doi: 10.1038/ni.3515. - DOI - PMC - PubMed
    1. Dos Santos FL, Gushi LT, Luiz WB, Amorim JH. Seeking flavivirus cross-protective immunity. Front Immunol. 2019;10:2260. doi: 10.3389/fimmu.2019.02260. - DOI - PMC - PubMed

MeSH terms

Full text links
Springer full text link Springer Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /